Ozempic (semaglutide SC once-weekly) / Novo Nordisk 
Welcome,         Profile    Billing    Logout  
 12 Diseases   138 Trials   138 Trials   3994 News 


«12...2425262728293031323334...3940»
  • ||||||||||  Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Journal:  Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide. (Pubmed Central) -  Jul 2, 2021   
    In the REWIND trial, dulaglutide reduced cardiovascular (CV) risk versus placebo in patients with type 2 diabetes in both the "established CV disease" (CVD) and "CV risk factor" subgroups...After re-categorization, the risk of MACE was significantly lower with semaglutide versus placebo in the established CVD subgroup (hazard ratio [HR], 95% confidence interval [CI]: 0.74 [0.59, 0.92]) and non-significantly lower in the CV risk factor subgroup (HR, 95% CI: 0.84 [0.55, 1.28]) (P-interaction=0.60). These results suggest that the CV effects of semaglutide may extend to patients with T2D across the CV risk continuum.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    #Wegovy? (Twitter) -  Jun 30, 2021   
  • ||||||||||  Rybelsus (semaglutide oral) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Clinical, Journal, HEOR:  Exploring the Appropriate Price of Semaglutide for Type 2 Diabetes Patients Based on Cost-Utility Analysis in China. (Pubmed Central) -  Jun 29, 2021   
    Under the assumption that the annual cost of semaglutide is equal to that of OD empagliflozin, OW semaglutide was superior to OD empagliflozin due to its higher quality adjusted life years and lower total costs...Ultimately, the cost-utility results with annual costs of semaglutide of $877.43 and $667.04 were robust to probabilistic sensitivity analysis and scenario analysis. In conclusion, the annual cost of semaglutide appears to be appropriate between $667.04 and $877.43 for T2D patients in China.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Clinical, Journal, Real-world evidence:  Semaglutide Once Weekly in Persons with Type 2 Diabetes: Real-world Analysis of the Canadian LMC Diabetes Registry (SPARE Study). (Pubmed Central) -  Jun 26, 2021   
    These data suggest that tirzepatide's activity on GE is comparable to that of selective GLP-1RAs. This retrospective observational study demonstrated that GLP-1 RA naïve adults with T2D initiating semaglutide in a real-world clinical practice had a statistically and clinically significant reduction in HbA1c and body weight after three to six months, regardless of semaglutide dose or order of semaglutide therapy, with no significant change in reported incidence of hypoglycemia.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Clinical, Journal:  Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials. (Pubmed Central) -  Jun 26, 2021   
    P3
    Patients with microvascular disease were shown to have increased risk of major adverse cardiovascular events (MACE) compared with patients without microvascular disease (hazard ratio [95% confidence interval] in LEADER: 1.15 [1.03;1.29] p = 0.0136; SUSTAIN 6: 1.56 [1.14;2.17] p = 0.0064). Liraglutide and semaglutide consistently reduced cardiovascular risk in patients with and without microvascular disease.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    [VIRTUAL] Real-World Effectiveness of Newly Initiated Once-Weekly Semaglutide (sema OW) by Prescriber Specialty () -  Jun 25, 2021 - Abstract #ADA2021ADA_2842;    
    The lack of statistical heterogeneity from these cardiorenal outcomes implies that liraglutide and semaglutide may be beneficial for many patients and is likely not to depend on their baseline BMI, but further study is needed. Similar pre/post reductions in A1c were observed when initiating sema OW in T2D GLP-1 agonist naïve patients being treated by PCPs and Endos.
  • ||||||||||  Victoza (liraglutide) / Novo Nordisk, Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Clinical, Review, Journal:  Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists. (Pubmed Central) -  Jun 23, 2021   
    Owing to their effectiveness in reducing body weight, once-daily subcutaneous administration of liraglutide 3.0 mg has been approved, and once-weekly subcutaneous administration of semaglutide 2.4 mg is being investigated in phase III trials, for obesity management. Considerations regarding adverse effects and contraindications for different drug classes are provided to help guide treatment decision-making when considering pharmacotherapy for weight management in patients with obesity.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Clinical, Review, Journal:  Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes. (Pubmed Central) -  Jun 22, 2021   
    This review puts the latest clinical data from the marketed QW GLP-1 RAs into context with results from older Phase 3 trials, to enable pharmacists and HCPs to make informed treatment decisions. Each of the three QW GLP-1 RAs has their own safety profile, which should be considered when choosing the optimal treatment for patients.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Review, Journal:  Managing the multifaceted nature of type 2 diabetes using once-weekly injectable GLP-1 receptor agonist therapy. (Pubmed Central) -  Jun 22, 2021   
    From the literature, this appears to be the first review of the evidence supporting the multifaceted role of QW GLP-1 RAs in T2D, with particular emphasis on their use in comorbid conditions, as well as associated potential financial and well-being benefits. The results suggest that QW GLP-1 RAs may be an attractive treatment option for improving glycaemic control in T2D, especially in individuals with (or at risk of) additional comorbidities or health complications.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Clinical, Review, Journal:  Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes. (Pubmed Central) -  Jun 22, 2021   
    This review collates recently published data and previously published Phase 3 results to allow pharmacists and other HCPs to understand all of the efficacy data available and the corresponding impact on treatment guidelines. QW GLP-1 RAs are emerging as important therapeutic options for people with T2D as they offer a spectrum of benefits extending beyond glycaemic control, but it is important to be aware of their efficacy differences when prescribing and discussing them with patients.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Clinical, Review, Journal:  Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes. (Pubmed Central) -  Jun 22, 2021   
    This article provides an overview of the results from QW GLP-1 RA CVOTs, including the recently published results for dulaglutide, and places them within the broader T2D treatment landscape to help HCPs make informed decisions in daily practice. The QW GLP-1 RAs with benefits reaching beyond glycaemic control can provide a comprehensive treatment option for people with T2D at high risk of CVD, with CVD or chronic kidney disease.
  • ||||||||||  Ozempic (semaglutide SC once-weekly) / Novo Nordisk
    Trial initiation date:  NOVO-GLP1: Treatment of GLP-1 for Diabetic Bariatric Patients (clinicaltrials.gov) -  Jun 16, 2021   
    P4,  N=126, Not yet recruiting, 
    NLR is readily accessible from routinely obtained and inexpensive blood counts; it could offer a convenient, clinically useful inflammatory biomarker for CV risk prediction in this population. Initiation date: Apr 2021 --> Jul 2021
  • ||||||||||  Farxiga (dapagliflozin) / Ono Pharma, AstraZeneca
    [VIRTUAL] Coming soon: new drugs for treatment of youth with type 2 diabetes0 () -  Jun 9, 2021 - Abstract #ESPE2021ESPE_31;    
    Metformin was the first and only drug approved in 1999 for use in youth with type 2 diabetes (T2D) based on a small, randomized clinical trial...However, formation of the Pediatric Diabetes Consortium (PDC) of leading pediatric diabetes treatment centers in the US was an important turning point, since a primary aim of the PDC is to improve the care of adolescents with T2D by making drugs with proven effectiveness in adults available to youth with T2D. The PDC has already accomplished its current primary goal by participation in the following studies: Exenatide by once weekly injection (approved) Oral dapagliflozin (in analysis of study outcomes) Phase III dapagliflozin and saxagliptin vs placebo study (nearing completion of randomization) Dinamo Phase III empagliflozin and linagliptin vs placebo (nearing completion of enrollment) Dinamo Mono study (in early recruitment phase) Liraglutide by daily injection (approved) Oral Semaglutide (in early recruitment phase) Phase III Alogliptin versus Placebo Study (nearing completion) We strongly believe that the results of these and future randomized clinical trials will transform the care of youth with type 2 diabetes in the future.